Novo Nordisk boosts Wegovy access with discounts as FDA bans compounded semaglutide drugs and cracks down on weight-loss copycats.

FDA Commissioner Dr. Marty Makary said Thursday that the United States needs to transform its health care approach from ...

VinFuture Prize holds the distinction of being the first major international science and technology award to recognize and ...

Despite low obesity rates, Korea sees high demand for Wegovy, prompting misuse and regulatory concerns amid societal ...

Covid vaccines from Pfizer and Moderna must carry expanded warning labels informing patients of the risk of rare heart inflammation. The FDA is also cracking down on off-brand GLP-1 drugs. Other ...

The Food and Drug Administration is cracking down on copycat versions of Ozempic — the brand name of semaglutide — and Zepbound — the brand name of tirzepatide, threatening a workaround that allowed ...

Researchers are beginning to wonder if blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in preventing ...

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

Novo Nordisk reduces its starter dose prices through telehealth platforms to encourage weaning patients off compounded copycats.

Even the packaged goods industry is getting in on the GLP-1-shift game. Conagra, the North American packaged foods company ...

Attorneys for groups trying to ballot measures before Florida voters next year say their First Amendment rights are being ...